Order Article Reprints

Roßwag S, Cotarelo CL, Pantel K, Riethdorf S, Sleeman JP, Schmidt M, Thaler S. Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer. Cancers. 2021; 13(8):1810. https://doi.org/10.3390/cancers13081810

Roßwag, Sven, Cristina L. Cotarelo, Klaus Pantel, Sabine Riethdorf, Jonathan P. Sleeman, Marcus Schmidt, and Sonja Thaler. 2021. "Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer" Cancers 13, no. 8: 1810. https://doi.org/10.3390/cancers13081810

Roßwag, S., Cotarelo, C. L., Pantel, K., Riethdorf, S., Sleeman, J. P., Schmidt, M., & Thaler, S. (2021). Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer. Cancers, 13(8), 1810. https://doi.org/10.3390/cancers13081810